235 related articles for article (PubMed ID: 36000541)
1. HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma.
Tabernero J; Shen L; Elimova E; Ku G; Liu T; Shitara K; Lin X; Boyken L; Li H; Grim J; Ajani J
Future Oncol; 2022 Sep; 18(29):3255-3266. PubMed ID: 36000541
[TBL] [Abstract][Full Text] [Related]
2. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
3. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Catenacci DV; Rosales M; Chung HC; H Yoon H; Shen L; Moehler M; Kang YK
Future Oncol; 2021 Apr; 17(10):1155-1164. PubMed ID: 33263418
[TBL] [Abstract][Full Text] [Related]
4. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
[TBL] [Abstract][Full Text] [Related]
5. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Janjigian YY; Kawazoe A; Yañez P; Li N; Lonardi S; Kolesnik O; Barajas O; Bai Y; Shen L; Tang Y; Wyrwicz LS; Xu J; Shitara K; Qin S; Van Cutsem E; Tabernero J; Li L; Shah S; Bhagia P; Chung HC
Nature; 2021 Dec; 600(7890):727-730. PubMed ID: 34912120
[TBL] [Abstract][Full Text] [Related]
6. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.
Klempner SJ; Maron SB; Chase L; Lomnicki S; Wainberg ZA; Catenacci DVT
Oncologist; 2019 Apr; 24(4):475-482. PubMed ID: 30470690
[TBL] [Abstract][Full Text] [Related]
7. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
[TBL] [Abstract][Full Text] [Related]
8. [Pembrolizumab with trastuzumab and chemotherapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS≥1].
Lévêque I; Spitzer E
Bull Cancer; 2024 Feb; 111(2):130-132. PubMed ID: 38071114
[No Abstract] [Full Text] [Related]
9. The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.
Lu Z; Yang S; Luo X; Shi Y; Lee JS; Deva S; Liu T; Chao Y; Zhang Y; Huang R; Xu Y; Shen Z; Shen L
Gastric Cancer; 2022 Sep; 25(5):943-955. PubMed ID: 35778636
[TBL] [Abstract][Full Text] [Related]
10. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.
Chung HC; Bang YJ; S Fuchs C; Qin SK; Satoh T; Shitara K; Tabernero J; Van Cutsem E; Alsina M; Cao ZA; Lu J; Bhagia P; Shih CS; Janjigian YY
Future Oncol; 2021 Feb; 17(5):491-501. PubMed ID: 33167735
[TBL] [Abstract][Full Text] [Related]
11. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.
Catenacci DVT; Kang YK; Yoon HH; Shim BY; Kim ST; Oh DY; Spira AI; Ulahannan SV; Avery EJ; Boland PM; Chao J; Chung HC; Gardner F; Klempner SJ; Lee KW; Oh SC; Peguero J; Sonbol MB; Shen L; Moehler M; Sun J; Li D; Rosales MK; Park H
ESMO Open; 2022 Oct; 7(5):100563. PubMed ID: 36029651
[TBL] [Abstract][Full Text] [Related]
12. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer.
Grávalos C; Gómez-Martín C; Rivera F; Alés I; Queralt B; Márquez A; Jiménez U; Alonso V; García-Carbonero R; Sastre J; Colomer R; Cortés-Funes H; Jimeno A
Clin Transl Oncol; 2011 Mar; 13(3):179-84. PubMed ID: 21421462
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
Porth I; Hirsch D; Ceribas Y; Weidner P; Weichert W; Götze TO; Perner S; Luley K; Heyer CM; de la Torre C; Hofheinz RD; Lorenzen S; Gaiser T
Eur J Cancer; 2023 Apr; 183():119-130. PubMed ID: 36848831
[TBL] [Abstract][Full Text] [Related]
15. KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.
Tabernero J; Bang YJ; Van Cutsem E; Fuchs CS; Janjigian YY; Bhagia P; Li K; Adelberg D; Qin SK
Future Oncol; 2021 Aug; 17(22):2847-2855. PubMed ID: 33975465
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
[TBL] [Abstract][Full Text] [Related]
17. PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.
Deguchi Y; Okabe H; Oshima N; Hisamori S; Minamiguchi S; Muto M; Sakai Y
Gastric Cancer; 2017 May; 20(3):416-427. PubMed ID: 27517839
[TBL] [Abstract][Full Text] [Related]
18. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Bartley AN; Washington MK; Ventura CB; Ismaila N; Colasacco C; Benson AB; Carrato A; Gulley ML; Jain D; Kakar S; Mackay HJ; Streutker C; Tang L; Troxell M; Ajani JA
Am J Clin Pathol; 2016 Dec; 146(6):647-669. PubMed ID: 28077399
[TBL] [Abstract][Full Text] [Related]
19. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Tabernero J; Hoff PM; Shen L; Ohtsu A; Shah MA; Cheng K; Song C; Wu H; Eng-Wong J; Kim K; Kang YK
Lancet Oncol; 2018 Oct; 19(10):1372-1384. PubMed ID: 30217672
[TBL] [Abstract][Full Text] [Related]
20. Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Al-Batran SE; Moorahrend E; Maintz C; Goetze TO; Hempel D; Thuss-Patience P; Gaillard VE; Hegewisch-Becker S
Oncologist; 2020 Aug; 25(8):e1181-e1187. PubMed ID: 32311799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
